TACSTD2 and triple-negative breast carcinoma: TROP2 is a clinically validated target that has been successfully targeted with sacituzumab govitecan-hziy (Trodelvy®), a TROP2-directed antibody drug conjugate (ADC) approved for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer (24).